CN115298194A - Vipr2拮抗肽 - Google Patents

Vipr2拮抗肽 Download PDF

Info

Publication number
CN115298194A
CN115298194A CN202180022969.7A CN202180022969A CN115298194A CN 115298194 A CN115298194 A CN 115298194A CN 202180022969 A CN202180022969 A CN 202180022969A CN 115298194 A CN115298194 A CN 115298194A
Authority
CN
China
Prior art keywords
group
leu
pro
amino acid
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180022969.7A
Other languages
English (en)
Chinese (zh)
Inventor
坂元孝太郎
吾乡由希夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichimaru Pharcos Co Ltd
Original Assignee
Ichimaru Pharcos Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichimaru Pharcos Co Ltd filed Critical Ichimaru Pharcos Co Ltd
Publication of CN115298194A publication Critical patent/CN115298194A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180022969.7A 2020-03-30 2021-03-19 Vipr2拮抗肽 Pending CN115298194A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-059721 2020-03-30
JP2020059721 2020-03-30
PCT/JP2021/011316 WO2021200259A1 (ja) 2020-03-30 2021-03-19 Ｖｉｐｒ２アンタゴニストペプチド

Publications (1)

Publication Number Publication Date
CN115298194A true CN115298194A (zh) 2022-11-04

Family

ID=77928204

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180022969.7A Pending CN115298194A (zh) 2020-03-30 2021-03-19 Vipr2拮抗肽

Country Status (5)

Country Link
US (1) US20230174582A1 (https=)
EP (1) EP4137502A4 (https=)
JP (2) JP7698318B2 (https=)
CN (1) CN115298194A (https=)
WO (1) WO2021200259A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7339471B1 (ja) * 2022-02-25 2023-09-05 一丸ファルコス株式会社 癌転移抑制用のｖｉｐｒ２アンタゴニストペプチド
JP7417010B1 (ja) * 2022-03-31 2024-01-17 国立大学法人 香川大学 癌免疫増強用のｖｉｐｒ２アンタゴニストペプチド

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001870A (zh) * 2004-06-16 2007-07-18 通用电气医疗集团股份有限公司 基于肽的化合物
CN108218971A (zh) * 2016-12-21 2018-06-29 海南大学 α-芋螺毒素肽TxID新突变体、其药物组合物及用途
CN109689679A (zh) * 2016-09-13 2019-04-26 第一三共株式会社 血小板反应蛋白1结合肽
WO2023190812A1 (ja) * 2022-03-31 2023-10-05 国立大学法人香川大学 癌免疫増強用のｖｉｐｒ２アンタゴニストペプチド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109943A (en) * 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US6750194B1 (en) 2000-10-23 2004-06-15 The Procter & Gamble Company Methods of identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
JP5280682B2 (ja) * 2004-06-16 2013-09-04 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
CN101296708B (zh) 2005-10-26 2011-12-07 伊莱利利公司 选择性vpac2受体肽激动剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001870A (zh) * 2004-06-16 2007-07-18 通用电气医疗集团股份有限公司 基于肽的化合物
CN109689679A (zh) * 2016-09-13 2019-04-26 第一三共株式会社 血小板反应蛋白1结合肽
CN108218971A (zh) * 2016-12-21 2018-06-29 海南大学 α-芋螺毒素肽TxID新突变体、其药物组合物及用途
WO2023190812A1 (ja) * 2022-03-31 2023-10-05 国立大学法人香川大学 癌免疫増強用のｖｉｐｒ２アンタゴニストペプチド

Also Published As

Publication number Publication date
JPWO2021200259A1 (https=) 2021-10-07
JP2025120320A (ja) 2025-08-15
US20230174582A1 (en) 2023-06-08
EP4137502A4 (en) 2024-02-28
EP4137502A1 (en) 2023-02-22
WO2021200259A1 (ja) 2021-10-07
JP7698318B2 (ja) 2025-06-25

Similar Documents

Publication Publication Date Title
US12600749B2 (en) Compstatin analogues and their medical uses
JP2025120320A (ja) Ｖｉｐｒ２アンタゴニストペプチド
BRPI0715407A2 (pt) peptÍdeos e seus derivados funcionalmente equivalentes, composiÇÕes farmacÊuticas e usos dos mesmos
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
KR20140038435A (ko) 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제
WO2010004003A2 (en) Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
US8026218B2 (en) Bifunctional analgesic compounds for opioid receptor agonists and neurokinin-1 receptor antagonists
CN106967151B (zh) 多位点组合修饰的内吗啡肽类似物及其合成和应用
US20040122013A1 (en) Analogs of nocicettin
EP3970801A1 (en) Ras inhibitory peptide
CA2418793C (en) Pharmaceutical composition comprising an analgesic peptide
WO2022117116A1 (zh) 一种α9α10nAChR抑制活性肽及其应用
JP6952320B2 (ja) 新規ｎｋ３受容体アゴニスト
KR20250140094A (ko) Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
EP4180446A1 (en) Cyclic peptide, peptide complex, and drug composition containing said cyclic peptide and/or said peptide complex
JP2025102922A (ja) 新規ｌｒｐ１結合ペプチド
US10562935B2 (en) Stapled peptides and uses thereof
WO2024043249A1 (ja) 環状ペプチドまたはその塩、およびｍｄｍｘ阻害剤
ES3005857T3 (en) Novel peptoids and use thereof for preventing or treating chronic pain
WO2018035615A1 (en) Compositions and methods for the treatment of inflammatory bowel diseases
AU2024314499A1 (en) Modified polypeptide and use thereof in field of analgesia
EA051613B1 (ru) Ингибиторы фактора с3 системы комплемента и варианты их применения в медицине
JPWO2015083816A1 (ja) 新規ｎｋ３受容体アゴニスト
HK40069562B (zh) 钙敏感受体激动剂化合物及其应用
Penke et al. Analogue and conformational studies on peptides, hormones and other biologically active peptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination